Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus-1 associated myelopathy. (Q55239076)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29473309%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

title

Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus-1 associated myelopathy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29473309%20AND%20SRC:MED&resulttype=core&format=json

Human T-lymphotropic virus 1

18 March 2020

main subject

0 references

author name string

Tomohiro Matsuo

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29473309%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Tatsufumi Nakamura

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29473309%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Katsuya Satoh

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29473309%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

publication date

22 February 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29473309%20AND%20SRC:MED&resulttype=core&format=json

Lower urinary tract symptoms

18 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29473309%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29473309%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29473309%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

page(s)

O65-O70

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29473309%20AND%20SRC:MED&resulttype=core&format=json

Voiding dysfunction in patients with human T-lymphotropic virus type-1-associated myelopathy (HAM).

18 March 2020

cites work

1 reference

12 December 2020

HTLV-I associated myelopathy, a new clinical entity.

1 reference

12 December 2020

An HTLV-I vaccine: why, how, for whom?

1 reference

12 December 2020

Seminars in medicine of the Beth Israel Hospital, Boston. Pathogenesis of diseases induced by human lymphotropic virus type I infection

1 reference

12 December 2020

Multiple viral strategies of HTLV-1 for dysregulation of cell growth control

1 reference

12 December 2020

Urinary symptoms associated with human T-cell lymphotropic virus type I infection: evidence of urinary manifestations in large group of HTLV-I carriers

1 reference

12 December 2020

Urodynamic features of the voiding dysfunction in HTLV-1 infected individuals

1 reference

12 December 2020

Urinary and sexual manifestations of patients infected by HTLV-I.

1 reference

12 December 2020

Corticosteroid therapy in TSP/HAM patients: the results from a 10 years open cohort.

1 reference

12 December 2020

The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis

1 reference

12 December 2020

Psychometric analysis of international prostate symptom score for female lower urinary tract symptoms

1 reference

12 December 2020

Oral manifestations of human T-cell lymphotropic virus infection in adult patients from Brazil.

1 reference

12 December 2020

Efficacy and tolerability of solifenacin in patients aged ≥ 65 years with overactive bladder: post-hoc analysis of 2 open-label studies

1 reference

12 December 2020

Neurological symptoms and signs in HTLV-1 patients with overactive bladder syndrome

1 reference

12 December 2020

Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis

1 reference

12 December 2020

Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial

1 reference

12 December 2020

Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder

1 reference

12 December 2020

Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study.

1 reference

12 December 2020

Mirabegron for overactive bladder: a novel, first-in-class β3-agonist therapy

1 reference

12 December 2020

OnabotulinumtoxinA (Botox(®)): a review of its use in the treatment of urinary incontinence in patients with multiple sclerosis or subcervical spinal cord injury

1 reference

12 December 2020

Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year

1 reference

12 December 2020

The use of botulinum toxin type A in the treatment of HTLV-1-associated overactive bladder refractory to conventional therapy

1 reference

12 December 2020

Reevaluation for clinical manifestations of HTLV-I-seropositive patients with Sjögren's syndrome.

1 reference

12 December 2020

Nation-wide epidemiological study of Japanese patients with rare viral myelopathy using novel registration system (HAM-net).

1 reference

12 December 2020

The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men.

1 reference

12 December 2020

Prevalence of Sjögren's syndrome in Brazilian patients infected with human T-cell lymphotropic virus

1 reference

12 December 2020

Identifiers

DOI

10.1111/LUTS.12218

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29473309%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference